Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/20/20/07/20200745-80b5-2a8a-6f6a-ccd64c86a437/mza_5050217037122635137.jpg/600x600bb.jpg
ASTCT Talks
ASTCT
65 episodes
1 day ago
ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. We hope you enjoy listening!
Show more...
Medicine
Health & Fitness
RSS
All content for ASTCT Talks is the property of ASTCT and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. We hope you enjoy listening!
Show more...
Medicine
Health & Fitness
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/10570906/10570906-1714156932227-b584a6194311e.jpg
Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know
ASTCT Talks
21 minutes 33 seconds
3 months ago
Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know

In this episode of ASTCT Talks, Dr. Rahul Banerjee sits down with Dr. Kenneth Lim and Dr. Yi Lin of Mayo Clinic to discuss a critical and emerging topic in CAR T-cell therapy: delayed neurotoxicities following cilta-cel treatment in multiple myeloma. They break down the clinical features of nerve palsies and Parkinsonism-like symptoms, share diagnostic and treatment strategies and explore emerging predictive markers like absolute lymphocyte count. Given that cilta-cel is increasingly being used in second-line myeloma treatment and is even being studied in first-line treatment to replace stem cell transplantation, this conversation is a timely and insightful look at improving patient outcomes in CAR T-cell therapy.

ASTCT Talks
ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. We hope you enjoy listening!